A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

Inclusion criteria:

Patients in the pooled OMB and pooled OCR cohorts are required to meet the following eligibility criteria:

* ≥1 incident claim for OMB (pooled OMB cohort) or OCR (pooled OCR cohort) in the patient identification period.
* No claims for OMB or OCR within the 12 months prior to the index date. The index date is the date of the first OMB or OCR claim.
* ≥2 outpatient (OP) medical claims (at least 30 days apart) with a diagnosis code for MS (International Classification of Diseases, Tenth Revision, Clinical Modification \[ICD-10-CM\] code: G35) in any position, with the first claim occurring in the 12 months prior to or on index date and the second claim up to 6 months after index date, or ≥1 inpatient (IP) claim with MS recorded as the primary diagnosis in the 12 months prior to or on index date.
* ≥18 years of age on index date.
* Continuous healthcare plan enrollment for ≥12 months prior to index date and ≥6 months after index date.
* Persistent use of OMB (pooled OMB cohort) or OCR (pooled OCR cohort) for ≥6 months after index date.

Patients in the treatment-naïve OMB and treatment-naïve OCR cohorts are required to meet the following eligibility criteria:

* Included in pooled OMB cohort or pooled OCR cohort.
* No claims for a disease-modifying therapy (DMT) used for the treatment of MS in the 12-month baseline period.

Exclusion criteria:

• Patients who do not meet the study inclusion criteria.

Other protocol-defined inclusion/exclusion criteria may apply.